Table 2. The changes of symptom scores and VUDS parameters in the onabotulinumtoxinA (BoNT-A) and placebo groups at baseline and 1 month after the first external urethral sphincter injection therapy within dysfunctional voiding (DV) and detrusor underactivity (DU) patients.
| DV |
DU |
||||||
|---|---|---|---|---|---|---|---|
| BoNT-A (N = 16) | Placebo (N = 15) | P value# | BoNT-A (N = 22) | Placebo (N = 9) | P value# | ||
| IPSS-V | BL | 12.7 ± 6.6 | 14.1 ± 5.8 | 17.0 ± 3.8 | 15.1 ± 8.4 | ||
| 1 mo | 8.3 ± 7.6* | 5.7 ± 5.8* | 0.089 | 16.0 ± 4.3 | 6.6 ± 8.2* | 0.036 | |
| IPSS-S | BL | 11.4 ± 4.3 | 12.1 ± 4.0 | 10.1 ± 3.8 | 9.8 ± 4.5 | ||
| 1 mo | 8.5 ± 3.7* | 6.3 ± 3.9* | 0.089 | 8.5 ± 3.9 | 8.4 ± 4.5 | 0.831 | |
| IPSS-T | BL | 24.1 ± 10.3 | 26.2 ± 7.8 | 27.1 ± 6.2 | 24.3 ± 10.7 | ||
| 1 mo | 16.8 ± 10.4* | 12.0 ± 8.0* | 0.026 | 24.4 ± 5.2* | 15.0 ± 11.8* | 0.002 | |
| QoL-I | BL | 4.4 ± 1.7 | 5.4 ± 1.0 | 4.6 ± 2.0 | 5.4 ± 0.9 | ||
| 1 mo | 2.8 ± 2.1* | 2.4 ± 2.1* | 0.089 | 3.0 ± 1.9* | 2.4 ± 1.8* | 0.107 | |
| PPBC | BL | 4.8 ± 1.4 | 5.4 ± 1.4 | 4.7 ± 1.9 | 4.4 ± 1.9 | ||
| 1 mo | 3.3 ± 1.9* | 2.5 ± 2.2* | 0.085 | 3.5 ± 2.1* | 3.0 ± 1.8* | 0.814 | |
| CBC (mL) | BL | 359.0 ± 172.6 | 334 ± 176 | 393.9 ± 141 | 497 ± 262.5 | ||
| 1 mo | 365.0 ± 154.4 | 354 ± 125.7 | 0.860 | 434.7 ± 199.4 | 369 ± 169.2 | 0.042 | |
| Pdet (cmH2O) | BL | 40.3 ± 23.0 | 35.6 ± 25.1 | 9.2 ± 16.4 | 9.1 ± 12.8 | ||
| 1 mo | 31.6 ± 22.3* | 32.1 ± 22.6 | 0.473 | 9.8 ± 10.0 | 27.9 ± 30.0 | 0.070 | |
| Qmax (mL/s) | BL | 6.4 ± 5.4 | 7.9 ± 5.2 | 4.5 ± 6.0 | 3.4 ± 3.7 | ||
| 1 mo | 11.1 ± 10.1* | 8.9 ± 4.7 | 0.099 | 8.8 ± 9.1* | 10.6 ± 9.2* | 0.445 | |
| Vol. (mL) | BL | 119.9 ± 82.2 | 136.3 ± 109 | 93.9 ± 130.9 | 45.9 ± 54.9 | ||
| 1 mo | 191.0 ± 140.1* | 117.5 ± 63.7 | 0.020 | 155.0 ± 142.0 | 200 ± 219.7 | 0.182 | |
| PVR (mL) | BL | 225.0 ± 200.7 | 198 ± 168.2 | 350.0 ± 174.6 | 415 ± 304.0 | ||
| 1 mo | 198.0 ± 179.1 | 156 ± 160.5 | 0.770 | 293.0 ± 233.1 | 131 ± 169.1* | 0.046 | |
| VE (%) | BL | 42.1 ± 27.8 | 44.9 ± 32.2 | 20.8 ± 28.5 | 17.0 ± 31.5 | ||
| 1 mo | 50.5 ± 34.6 | 52.8 ± 34.6 | 0.969 | 39.4 ± 36.0* | 61.6 ± 40.7* | 0.094 | |
#p value between the changes of the parameters after external urethral sphincter injection therapy in BoNT-A and placebo groups.
*p value <0.05 versus baseline.
BL, baseline; IPSS, International Prostate Symptom Score; IPSS-V, IPSS voiding subscore; IPSS-S: IPSS storage subscore; IPSS-T, total IPSS score; PPBC, Patient Perception of Bladder Condition score; QoL-I, quality of life index; CBC, cystometric bladder capacity; Pdet, detrusor voiding pressure; Qmax, maximal urinary flow rate; Vol., voided volume; PVR, post-void residual; VE, voiding efficiency.
Data are expressed as mean ± standard deviation.